Advanced search×
  1. Intrinsic cancer subtypes-next steps into personalized medicine.

    Cellular oncology (Dordrecht) 38(1):3 (2015) PMID 25586691

    Recent technological advances have significantly improved our understanding of tumor biology by means of high-throughput mutation and transcriptome analyses. The application of genomics has revealed the mutational landscape and the specific deregulated pathways in different tumor types. At a tra...
  2. Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness.

    PLoS ONE 10(7):e0132546 (2015) PMID 26167915 PMCID PMC4500593

    Lymphangioleiomyomatosis (LAM) is a rare lung-metastasizing neoplasm caused by the proliferation of smooth muscle-like cells that commonly carry loss-of-function mutations in either the tuberous sclerosis complex 1 or 2 (TSC1 or TSC2) genes. While allosteric inhibition of the mechanistic target ...
  3. Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.

    Oncotarget 4(9):1484 (2013) PMID 23986086 PMCID PMC3824528

    Cancer cells expressing constitutively active phosphatidylinositol-3 kinase (PI3K) are proliferative regardless of the absence of insulin, and they form dietary restriction (DR)-resistant tumors in vivo. Because the binding of insulin to its receptors activates the PI3K/AKT/mammalian target of r...
  4. Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.

    Breast Cancer Research and Treatment 134(3):1161 (2012) PMID 22772380

    One of the most efficacious primary therapies in HER2-positive breast cancer was published by the M.D. Anderson group in 2005. This randomized trial evaluated the addition of trastuzumab to a taxane-anthracycline based chemotherapy. Despite largely significant differences in pathological complet...
  5. Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: a prospective analysis of axillary or distant recurrence.

    Annals of Surgical Oncology 17(3):772 (2010) PMID 20183912

    The need for axillary lymph node dissection (ALND) in breast cancer patients with sentinel lymph node (SLN) micrometastases remains controversial. The aims of the study were to evaluate the locoregional failure and outcome of breast cancer patients with sentinel node micrometastases who did not ...
  6. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.

    Current Medical Research and Opinion 25(10):2533 (2009) PMID 19722781

    Febrile neutropenia (FN) is associated with disruption of planned chemotherapy and increased management costs. However, the economic impact of FN in Spanish clinical practice has not been documented hitherto. A multicenter, retrospective chart review of adults with breast or lung cancer or non-H...
  7. [Angiosarcoma in an irradiated breast: a case description].

    Actas Dermo-Sifiliográficas 96(9):602 (2005) PMID 16476306

    Post-radiotherapy cutaneous angiosarcomas have been described in different locations, including the breast. We present a case of cutaneous angiosarcoma of the breast, diagnosed 6 years after a carcinoma of the breast had been treated with radiation. The patient was a 44-year-old female with a hi...
  8. Angiosarcoma en mama irradiada: descripción de un caso

    Actas Dermo-Sifiliográficas 96(9):602 (2005)

    Se han descrito angiosarcomas cutáneos posradioterapia en diferentes localizaciones corporales, incluyendo la mama. Presentamos un caso de angiosarcoma cutáneo sobre una mama previamente irradiada diagnosticado a los 6 años de haber tratado el carcinoma mamario. Se trata de una mu...